Equity Profile

MLYS

Mineralys Therapeutics, Inc.

Health CareBiotechnology$2.1B

May6Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Mineralys Therapeutics, Inc. Beats on EPS, Stock Up 2.87%

Metric	Actual	Expected	Surprise
EPS	$-0.47	$-0.44	+7.30%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Mineralys Therapeutics, Inc. Beats on EPS, Stock Up 2.87%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.47	$-0.44	+7.30%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Mineralys Therapeutics reported a narrower loss than expected, which contributed to a positive stock reaction, with shares rising by 2.87%. The company did not provide revenue figures, and there was no additional commentary from management. Investors may view the EPS beat as a sign of improving financial performance, but the lack of guidance leaves uncertainty about future expectations.

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious health conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.44

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could signal growth potential.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious health conditions. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs, particularly in the treatment of hypertension and related disorders.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+6.74%

Avg Stock Reaction

+5.24%

Last Quarter Recap

In the last quarter, Mineralys reported an EPS of $-0.40, which was better than analysts' expectations. However, the stock reacted negatively, declining by 3.50% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a loss of $-0.44 per share this quarter, with no revenue anticipated. The company's ability to manage losses effectively will be closely watched.

Bull Case

If Mineralys can beat EPS expectations, it may indicate stronger operational efficiency and could boost investor confidence.

Bear Case

A larger-than-expected loss could raise concerns about the company's financial health and future viability, leading to a negative market reaction.

Key Metrics to Watch

EPS

$-0.44

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could signal growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS come in better than the consensus estimate of $-0.44?

A better-than-expected EPS could indicate improved cost management and operational efficiency, which would be crucial for investor confidence.

What are the company's plans for future revenue generation?

Insights into future revenue streams could significantly impact investor sentiment and perceptions of growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mineralys to improve its cost structure, as recent operational changes could lead to better-than-expected results.

Supporting Evidence

The company has a history of beating EPS estimates, with a 63% success rate in the last eight quarters.

Insider selling may indicate a cautious outlook, but it could also reflect individual financial strategies rather than company performance.

The options market is pricing in a significant move, suggesting that traders expect volatility, which could be due to positive developments not yet reflected in consensus.

Key Risk

If the company shows any signs of revenue generation or improved cost management, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating the company's ability to manage losses and generate future revenue, which will be critical for its valuation.

Bull Confirmed If

An EPS of $-0.38 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than $-0.48 would confirm the bear case, raising concerns about the company's financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±16.1%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.3% while MLYS has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

72.2%

Calls (5K)P/C Ratio: 0.04Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

38,722 sh

2 insiders

Net

$1.0M

Net selling

Most Active Insiders· 5 open-market trades

Chief Medical OfficerRodman David Malcom
$621,120.23

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mineralys beats EPS expectations, history suggests a positive stock reaction, averaging a +5.69% move.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss on EPS could lead to a decline, with history suggesting an average drop of +2.66% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost management strategies and their effectiveness.
2Details on potential revenue streams and timelines for future product launches.
3Management's outlook on market conditions and competitive landscape.
4Insights into ongoing clinical trials and their potential impact on future earnings.
5Responses to analyst questions regarding insider selling and its implications.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious health conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

$-0.44

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams could signal growth potential.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+6.74%

Avg Stock Reaction

+5.24%

Last Quarter Recap

In the last quarter, Mineralys reported an EPS of $-0.40, which was better than analysts' expectations. However, the stock reacted negatively, declining by 3.50% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a loss of $-0.44 per share this quarter, with no revenue anticipated. The company's ability to manage losses effectively will be closely watched.

Bull Case

If Mineralys can beat EPS expectations, it may indicate stronger operational efficiency and could boost investor confidence.

Bear Case

A larger-than-expected loss could raise concerns about the company's financial health and future viability, leading to a negative market reaction.

Key Metrics to Watch

EPS

$-0.44

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$0M

Although no revenue is expected this quarter, any updates on future revenue streams could signal growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS come in better than the consensus estimate of $-0.44?

A better-than-expected EPS could indicate improved cost management and operational efficiency, which would be crucial for investor confidence.

What are the company's plans for future revenue generation?

Insights into future revenue streams could significantly impact investor sentiment and perceptions of growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mineralys to improve its cost structure, as recent operational changes could lead to better-than-expected results.

Supporting Evidence

The company has a history of beating EPS estimates, with a 63% success rate in the last eight quarters.

Insider selling may indicate a cautious outlook, but it could also reflect individual financial strategies rather than company performance.

The options market is pricing in a significant move, suggesting that traders expect volatility, which could be due to positive developments not yet reflected in consensus.

Key Risk

If the company shows any signs of revenue generation or improved cost management, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating the company's ability to manage losses and generate future revenue, which will be critical for its valuation.

Bull Confirmed If

An EPS of $-0.38 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than $-0.48 would confirm the bear case, raising concerns about the company's financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±16.1%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.3% while MLYS has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

72.2%

Calls (5K)P/C Ratio: 0.04Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

38,722 sh

2 insiders

Net

$1.0M

Net selling

Most Active Insiders· 5 open-market trades

Chief Medical OfficerRodman David Malcom
$621,120.23

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mineralys beats EPS expectations, history suggests a positive stock reaction, averaging a +5.69% move.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss on EPS could lead to a decline, with history suggesting an average drop of +2.66% in such scenarios.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on cost management strategies and their effectiveness.
2Details on potential revenue streams and timelines for future product launches.
3Management's outlook on market conditions and competitive landscape.
4Insights into ongoing clinical trials and their potential impact on future earnings.
5Responses to analyst questions regarding insider selling and its implications.